In the meta-analysis, we only conducted the subgroup analyses for non-small cell lung cancer and small cell lung cancer, without fully considering the distribution of tumor subtypes in different studies to evaluate differences in the effects of erythropoietin treatment among different subtypes. This evidence concerns the gene EPO and non-small cell lung carcinoma.